疫苗股继续活跃，其中，康希诺AH股午后拉升，A股一度涨超16%报82.48元，股价创2023年12月以来新高；H股拉升一度涨近14%报48.55港元，股价创 2023年3月以来新高。 随着确诊病例数量的增加，以及世界卫生组织专家发出的警报，市场对相关疫苗的需求预期显著增强，刺激疫苗股获资金追捧。 消息面上，基孔肯雅热在广东佛山市的爆发继续成为市场关注的焦点。据广东省疾控局消息，2025年7月20日0时至7月26日24时，广东省新增报告2940例 基孔肯雅热本地病例，未报告重症和死亡病例。病例分布在佛山2882例，广州22例，中山18例，东莞、珠海、河源各3例，江门、阳江、肇庆各2例，清 远、深圳、湛江各1例。 ...

Group 1 - The Hang Seng Index rose by 0.68% while the Hang Seng Tech Index fell by 0.24% [1] - Heng Rui Medicine saw a significant increase of over 24% [1] - CanSino Biologics increased by over 10% [1] Group 2 - Ningde Times and Dongfang Zhenxuan both rose by over 6% [1] - Ganfeng Lithium experienced a decline of over 6% [1] - Mixue Group fell by nearly 5% [1]

Group 1 - The stock of CanSino Biologics (06185.HK) has experienced a significant surge, rising over 12% [1] - The trading volume for CanSino Biologics has exceeded 150 million Hong Kong dollars [1]

康希诺生物股份公司（以下简称"公司"）于近日收到国家药品监督管理局 核准签发的关于重组三价脊髓灰质炎疫苗（Sf-RVN细胞）（以下简称"重组脊 髓灰质炎疫苗"）的《药物临床试验批准通知书》。具体情况如下： 证券代码：688185 证券简称：康希诺 公告编号：2025-018 康希诺生物股份公司 关于重组三价脊髓灰质炎疫苗（Sf-RVN细胞）获得 药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、通知书基本情况 产品名称：重组三价脊髓灰质炎疫苗（Sf-RVN 细胞） 注册分类：预防用生物制品 1.2 类 申请事项：境内生产药品注册临床试验 申请人：康希诺生物股份公司、康希诺（上海）生物科技有限公司 通知书编号：2025LP01807 审批结论：根据《中华人民共和国药品管理法》《中华人民共和国疫苗管理 法》及有关规定，经审查，重组脊髓灰质炎疫苗符合药品注册的有关要求，同意 开展预防由脊髓灰质炎 I 型、II 型和 III 型病毒感染导致的脊髓灰质炎的临床试 验。 二、产品相关情况 公司的重组脊髓 ...

Core Viewpoint - CanSino Biologics has received approval from the National Medical Products Administration for the clinical trial of its trivalent inactivated poliovirus vaccine (Sf-RVN cells), indicating progress in vaccine development and potential market entry [1] Group 1: Company Developments - CanSino Biologics announced the receipt of the clinical trial approval notice for its trivalent inactivated poliovirus vaccine [1] - The vaccine is developed using protein structure design and VLP assembly technology, ensuring it does not contain viral genetic material, which contributes to its safety and immunogenicity [1] - The vaccine is currently undergoing Phase I/II clinical trials in Indonesia [1] Group 2: Regulatory and Clinical Trial Information - The approval from the National Medical Products Administration allows CanSino to proceed with clinical trials in accordance with national drug registration regulations and requirements [1]

Core Viewpoint - 康希诺 is actively advancing its vaccine development pipeline, focusing on innovative products and expanding its market presence both domestically and internationally [1][2][3] Group 1: Vaccine Development and Commercialization - 康希诺's 13-valent pneumonia conjugate vaccine PCV13i has significant advantages in product characteristics and production processes, showing excellent clinical results and safety profiles [3][4] - The company is targeting the commercialization of PCV13i, which overlaps with its existing product MCV4, enhancing marketing efficiency [4] - The four-valent meningococcal conjugate vaccine MCV4 has received acceptance for age expansion applications for 4-6 years and plans to submit for 18-59 years within the year [5] Group 2: Research and Development Progress - 康希诺 has established five major R&D platforms, with multiple products at various stages of development, including Tdcp for adolescents and adults, which has completed Phase III clinical trials [2][7] - The company is exploring therapeutic vaccine development and has a positive attitude towards expanding into innovative fields [8] - The infant DTcP vaccine's application for market approval has been accepted and is undergoing priority review, with plans for clinical trials for a combination vaccine [6][9] Group 3: Financial Position and Future Plans - As of March 2025, 康希诺 has approximately 34 billion RMB in funds, sufficient for current development needs, with no large-scale investment plans outside of its vaccine industrial park project [2][10] - Future financing plans will be considered based on market conditions and company development stages, with timely announcements to be made if necessary [10]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 2025年6月30日 | | --- | | 狀態: | | 截至月份: 新提交 | 致：香港交易及結算所有限公司 公司名稱: 康希諾生物股份公司 呈交日期: 2025年7月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06185 | 說明 | H 股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 132,670,900 | RMB | | 1 | RMB | | 132,670,900 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 132,670,900 | RMB | | 1 | RMB | | 1 ...

证券代码：688185 证券简称：康希诺 公告编号：2025-016 康希诺生物股份公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 6 月 4 日 （二） 股东大会召开的地点：天津市河东区卫国道 126 号天津东凯悦酒店二层 悦宾厅 1 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 275 | | --- | --- | | 其中：A 股股东人数 | 274 | | H 股股东人数 | 1 | | 2、出席会议的股东所持有的表决权数量 | 89,499,039 | | 股股东所持有表决权数量 其中：A | 46,684,269 | | 股股东所持有表决权数量 H | 42,814,770 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 36.23 | | 例（%） ...

FF301 截至月份: 2025年5月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康希諾生物股份公司 呈交日期: 2025年6月4日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | H | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06185 | 說明 | H 股 | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | 已發行股份總數 | | | 上月底結存 | | | 132,670,900 | 0 | | 132,670,900 | | 增加 / 減少 (-) | | | 0 | 0 | | | | 本月底結存 | | | 132,670,900 | 0 | | 132,670,900 | | 1. 股份分類 | 普通股 | 股份類別 | ...

Group 1 - The Hong Kong Innovation Drug Index (987018) has seen a strong increase of 2.33% as of May 21, 2025, with notable gains in constituent stocks such as CanSino Biologics (06185) up 8.87%, Junshi Biosciences (01877) up 8.16%, and Kelun Pharmaceutical (06821) up 7.02% [1] - The Hong Kong Innovation Drug ETF (159567) has risen by 1.56%, marking its fourth consecutive increase, with the latest price reported at 1.3 HKD. Over the past week, the ETF has accumulated an increase of 8.63% [1] - The trading activity for the Hong Kong Innovation Drug ETF has been robust, with an intraday turnover of 10.03% and a transaction volume of 171 million HKD, indicating active market participation. The average daily trading volume over the past month reached 736 million HKD, with the ETF's latest scale reaching 1.667 billion HKD, a new high in nearly a year [1] Group 2 - The CDMO sector is expected to see rapid growth driven by the increasing demand for chemical macromolecules and XDC CDMO production, particularly in polypeptides and oligonucleotides, presenting investment opportunities in the related industry chain [1] - The CRO sector is anticipated to benefit from improving overseas financing conditions and a gradual shift towards a rate-cutting environment, with expectations of revenue recovery for integrated CRO/CDMO and domestic preclinical CROs, suggesting potential valuation recovery opportunities [2] - The CRO sector has been significantly impacted by domestic and international financing challenges, but with supportive domestic policies, there is an expectation for gradual recovery, highlighting investment opportunities in clinical CROs [2]